Marcelo Figueiras is president of Laboratorios Richmond, a pharmaceutical company that has traditionally focused on the development of oncological, cardiovascular and HIV-AIDS products. In the context of the coronavirus pandemic, in February the company received ANMAT approval for the production and commercialization of both components of the Sputnik V vaccine. The company is carrying out the final manufacturing process of the vaccine in Argentina.